Scafidi v. B. Braun Medical, Inc.

CourtDistrict Court, M.D. Florida
DecidedJanuary 17, 2024
Docket8:22-cv-02772
StatusUnknown

This text of Scafidi v. B. Braun Medical, Inc. (Scafidi v. B. Braun Medical, Inc.) is published on Counsel Stack Legal Research, covering District Court, M.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Scafidi v. B. Braun Medical, Inc., (M.D. Fla. 2024).

Opinion

UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF FLORIDA TAMPA DIVISION

COURTNEY SCAFIDI,

Plaintiff,

v. Case No. 8:22-cv-2772-VMC-TGW

B. BRAUN MEDICAL, INC.,

Defendant. ______________________________/

ORDER This matter comes before the Court pursuant to Plaintiff Courtney Scafidi’s Motion for Partial Summary Judgment (Doc. # 54) and Defendant B. Braun Medical, Inc.’s Motion for Summary Judgment (Doc. # 60), both filed on October 17, 2023, in this Title VII and Florida Civil Rights Act (FCRA) religious discrimination and retaliation case. Both parties have responded (Doc. ## 69, 70) and replied. (Doc. ## 74, 75). For the reasons that follow, Braun’s Motion is granted in part and denied in part, and Scafidi’s Motion is denied. I. Background A. Braun’s Business and Vaccine Policy Braun is “a full line supplier of IV therapy products, including IV solutions, drug delivery systems, vascular access devices [], and infusion pumps,” which Braun markets and sells to hospitals and medical providers throughout the country. (Grispo Decl. ¶ 3). Scafidi worked as a Senior Hospital Account Manager for Braun in Florida. (Scafidi Depo. at 63:10-64:12 & Ex. 6). This was a sales position, and Scafidi’s job duties included making in-person, on-site sales of IV systems to clinical staff and hospital management at facilities within her territory and ensuring her customers

were trained on these systems. (Id. at 63:10-66:25). Prior to the COVID-19 pandemic, Scafidi spent most of her “time ‘on site’ at hospitals within [her] territor[y].” (Grispo Decl. ¶ 5). There were just over 100 hospitals in Scafidi’s territory. (Id.). When the COVID-19 pandemic began in 2020, most hospitals barred sales representatives from entering hospitals. (Id. at ¶ 6). This had a large impact on Braun’s sales operations. (Scafidi Depo. at 66:22-67:23; Lutseo Depo. at 21:12-23; Malo Depo. at 74:22-76:1). Prior to the vaccine, hospitals slowly began allowing vendor representatives to reenter healthcare

facilities, but only when essential and under strict conditions, i.e., masking requirements and distancing. (Grispo Decl. at ¶ 7). Braun restarted some new sales operations but was unable to resume its full array of pre- pandemic work, including the work performed by Scafidi. (Malo Depo. at 80:9-22). The goal was always to resume normal operations to continue to thrive as a company. (Id.). During the pandemic and before her termination in November 2021, Scafidi was mostly working from home and rarely going into hospitals. (Malo Depo. at 74:11-76:18). COVID-19 vaccines became available in early 2021. During this time, Braun constantly monitored the pandemic and its

fluid effect on both its workforce and its customers. (Malo Depo. at 32:4-15; Grispo Decl. at ¶ 8). As the vaccine rollout became more widespread, some of Braun’s customers and vendor credentialing services informed Braun that certain hospitals would soon require vendor employees (like Scafidi) to be fully vaccinated before entering patient facilities. (Lutseo Depo. at 24:21-27:23; Grispo Decl. at ¶ 9). Scafidi disputes that all hospital systems within her territory had or were planning to implement vaccine requirements for visiting salespeople. (Lutseo Depo. at 32:6- 19; Scafidi Depo. at 85:17-86:15). She also highlights that

many of the hospital systems in her territory allowed for religious exemptions to the vaccine with Scafidi able to submit exemption requests through each hospital system’s vendor credentialing system. (Scafidi Depo. at 85:17-86:15, 87:7-8). While most hospitals, through credentialing services, offered forms to allow vendor employees to request exemptions, they offered no guarantee that any healthcare facility would accept or accommodate any exemption to allow a vendor representative to perform the essential customer- facing functions of his or her job. (Lutseo Depo. at 22:9- 23:2; 40:9-25). Braun issued its own vaccination policy for customer-

facing employees working in patient-care settings on September 21, 2021. (Donigan Depo. at 14:22-15:3 & Ex. E). The policy provides in relevant part: As such, we will now require most field-based and customer-facing colleagues across the region to complete the full course of COVID-19 vaccination. This includes sales, clinical educators (including temps), clinical nurse consultants, clinical applications specialists, service technicians, marketing product managers, and marketing project managers or other employees who are required to visit customers as part of their normal job responsibilities. If you have received this email, you are required to be fully vaccinated against COVID-19 as part of your job responsibilities by Monday, November 1, 2021. (Id.). Attached to the email with this policy was a FAQ page. (Id.). The FAQ informed employees that they could apply for an exemption from the policy. (Id.). It also informed employees, under the question “Can I apply for another B. Braun role if I don’t get vaccinated?,” that “[e]mployees can apply for other non-customer-facing opportunities in accordance with the job posting policy, keeping in mind the deadline of November 1, 2021.” (Id.). According to Joe Grispo, Braun’s Senior Vice President of Sales and Chief Sales Officer, “[t]he decision to limit the scope of the mandatory policy to employees in patient- care settings was an attempt by [] Braun to balance on the front-end many competing interests, including the need as a

healthcare company to trust healthcare science; to keep the health and safety of vulnerable patient populations top-of- mind; to respect the health, safety, and rights of its employees; and to maintain its competitiveness in the marketplace by ensuring its salesforce was resuming pre-COVID operations as would be its competitors.” (Grispo Decl. at ¶ 11). Grispo avers that “Braun further determined that an undue burden would occur even if an appreciable number of customers within a given territory would allow employee access without vaccinations.” (Id. at ¶ 12). “This was because if even one of an unvaccinated sales representative’s customers or

prospective customers declined to honor a religious exemption request or decided not to allow for full facility access, it would create an intractable coverage problem, as well as an imbalance within the territories and the revenue associated with the territories for the sales representative and all of the counterparts with the same title.” (Id.); see also (Malo Depo. at 84:4-85:8). According to Grispo, “[e]xtrapolated over the scores of hospitals within a given territory, the resulting patchwork quilt of one-off exemptions would be both impossible to track and impossible to account for under [] Braun’s territorial compensation system.” (Grispo Decl. at ¶ 13). Thus, “Braun

would need to recalculate the sales dollars, not only from a geography standpoint, but also from a compensation standpoint to assure that, all employees were treated equally and that base salaries equated to the role’s responsibilities.” (Id.). “Moreover, the fluid and dynamic nature of the vaccine requirements that were rolling out at the time meant that [Braun] would have to constantly revamp the territories to ensure customer coverage and equitable compensation.” (Id.). Scafidi’s supervisor, Andrea Malo, testified that reconfigurations of territories to adjust to vaccination exemptions would have required involvement from compensation

analysts, to build quotas with the Vice President of Sales, human resources, the Chief Financial Officer, and ultimately the CEO. (Malo Depo. at 85:9-86:22). When Braun had reconfigured territories in the past, that restructuring process had taken “at least 18 months.” (Id. at 87:15-88:6). For her part, Scafidi notes that her exemption denial letter did not mention any administrative difficulties or costs as the reason for the denial. (Doc.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Vickie Cox Edmondson v. Board of Trustees
258 F. App'x 250 (Eleventh Circuit, 2007)
Jeffery v. Sarasota White Sox, Inc.
64 F.3d 590 (Eleventh Circuit, 1995)
Mize v. Jefferson City Board of Education
93 F.3d 739 (Eleventh Circuit, 1996)
Allen v. Tyson Foods, Inc.
121 F.3d 642 (Eleventh Circuit, 1997)
Shotz v. City of Plantation, FL
344 F.3d 1161 (Eleventh Circuit, 2003)
Hickson Corp. v. Northern Crossarm Co.
357 F.3d 1256 (Eleventh Circuit, 2004)
United States v. Seeger
380 U.S. 163 (Supreme Court, 1965)
Wisconsin v. Yoder
406 U.S. 205 (Supreme Court, 1972)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Dixon v. the Hallmark Companies, Inc.
627 F.3d 849 (Eleventh Circuit, 2010)
Marvin Morris v. Harold Ross
663 F.2d 1032 (Eleventh Circuit, 1981)
United States v. Frank M. Oakley
744 F.2d 1553 (Eleventh Circuit, 1984)
Samples v. City Of Atlanta
846 F.2d 1328 (Eleventh Circuit, 1988)

Cite This Page — Counsel Stack

Bluebook (online)
Scafidi v. B. Braun Medical, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/scafidi-v-b-braun-medical-inc-flmd-2024.